Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
CPIX 
Cumberland Pharmaceuticals Inc (CPIX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/06/2026: CPIX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $8.5
1 Year Target Price $8.5
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -2.18% | Avg. Invested days 22 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/06/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 59.84M USD | Price to earnings Ratio - | 1Y Target Price 8.5 |
Price to earnings Ratio - | 1Y Target Price 8.5 | ||
Volume (30-day avg) 1 | Beta -0.53 | 52 Weeks Range 1.85 - 7.25 | Updated Date 01/6/2026 |
52 Weeks Range 1.85 - 7.25 | Updated Date 01/6/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.24 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -8.06% | Operating Margin (TTM) -23.7% |
Management Effectiveness
Return on Assets (TTM) -2.86% | Return on Equity (TTM) -13.28% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 54568576 | Price to Sales(TTM) 1.45 |
Enterprise Value 54568576 | Price to Sales(TTM) 1.45 | ||
Enterprise Value to Revenue 1.32 | Enterprise Value to EBITDA 18.38 | Shares Outstanding 14956627 | Shares Floating 8733324 |
Shares Outstanding 14956627 | Shares Floating 8733324 | ||
Percent Insiders 41.63 | Percent Institutions 22.93 |
Upturn AI SWOT
Cumberland Pharmaceuticals Inc
Company Overview
History and Background
Cumberland Pharmaceuticals Inc. was founded in 1994 and is headquartered in Nashville, Tennessee. The company is a specialty pharmaceutical company focused on the development, manufacturing, and marketing of prescription products. Historically, Cumberland has focused on developing and acquiring products in areas such as critical care, hospital-based therapeutics, and gastroenterology.
Core Business Areas
- Hospital-Based Therapeutics: Development and marketing of prescription drugs typically used in hospital settings, often for critical care or specialized treatments. This segment focuses on products with a strong clinical rationale and established efficacy.
- Gastroenterology Products: Focus on prescription medications for the treatment of gastrointestinal disorders, aiming to address unmet needs in this therapeutic area.
Leadership and Structure
Cumberland Pharmaceuticals Inc. operates with a management team responsible for its strategic direction, product development, sales, and marketing. Specific leadership details, such as CEO, CFO, and board members, are subject to change and would require current financial filings for precise information.
Top Products and Market Share
Key Offerings
- Product Name 1: CORTROPHINu00ae Gel (repository corticotropin injection). Description: A gel formulation of corticotropin used to treat exacerbations of multiple sclerosis and certain rheumatic, "allergic," dermatologic, ophthalmic, respiratory, renal, and gastrointestinal conditions. Market Share: Specific market share data for CORTROPHIN Gel is not publicly detailed, but it competes in the broader corticosteroid and ACTH market. Competitors: Brands like H.P. Acthar Gel (Mallinckrodt Pharmaceuticals), and generic injectable corticosteroids.
- Product Name 2: VAGENu00ae (vaginal suppositories). Description: A medication used for certain gynecological conditions. Market Share: Niche product, specific market share not readily available. Competitors: Other vaginal therapies and treatments for related conditions.
- Product Name 3: OTR-AFu2122 (acetylcholine chloride ophthalmic solution). Description: A solution used in ophthalmic surgery. Market Share: Niche market for ophthalmic surgical aids. Competitors: Other ophthalmic solutions and miotics used in cataract and intraocular lens surgery.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by extensive research and development, stringent regulatory oversight, patent protection, and intense competition. Key trends include the rise of specialty drugs, biosimil competition, and increasing healthcare costs. The hospital-based therapeutics and specialty pharmaceutical segments are driven by clinical efficacy, physician adoption, and payer reimbursement.
Positioning
Cumberland Pharmaceuticals Inc. positions itself as a specialty pharmaceutical company with a focus on acquiring, developing, and commercializing niche products, particularly those with a strong presence in hospital settings. Its competitive advantages lie in its established distribution channels within hospitals and its ability to identify and bring to market products addressing specific medical needs. However, its market position is relatively small compared to large, diversified pharmaceutical giants.
Total Addressable Market (TAM)
The TAM for Cumberland's products is fragmented across several therapeutic areas, including critical care, hospital pharmaceuticals, and gastroenterology. The overall TAM for these segments is in the billions of dollars globally. Cumberland Pharmaceuticals Inc. targets specific niches within these larger markets, meaning its serviceable obtainable market (SOM) is a smaller, more defined portion.
Upturn SWOT Analysis
Strengths
- Focus on niche therapeutic areas with less direct competition from blockbuster drugs.
- Established relationships with hospital systems and healthcare providers.
- Experience in product development and acquisition within specialty pharmaceuticals.
Weaknesses
- Limited pipeline and reliance on a few key products.
- Smaller company size compared to major pharmaceutical players, limiting R&D and marketing budgets.
- Vulnerability to patent expirations and generic competition for its products.
Opportunities
- Acquisition of new products or companies to expand its portfolio.
- Expansion into new geographic markets.
- Leveraging its expertise in hospital-based therapeutics to identify unmet needs.
Threats
- Increased competition from both established and emerging pharmaceutical companies.
- Changes in healthcare regulations and reimbursement policies.
- Adverse clinical trial outcomes or product recalls.
- The emergence of new, more effective treatments that displace existing products.
Competitors and Market Share
Key Competitors
- Mallinckrodt Pharmaceuticals (MNK)
- Amneal Pharmaceuticals (AMRX)
- Teva Pharmaceutical Industries (TEVA)
Competitive Landscape
Cumberland Pharmaceuticals Inc. operates in a competitive landscape where it faces larger, more established pharmaceutical companies with greater R&D budgets and market reach. Its advantage lies in its focused approach to niche markets and hospital systems. However, it is vulnerable to price pressures, patent cliffs, and the introduction of superior therapeutic alternatives by its competitors.
Growth Trajectory and Initiatives
Historical Growth: Cumberland's historical growth has likely been driven by the successful launch and commercialization of its acquired or developed products, as well as strategic acquisitions. Growth would be measured by revenue increases and profitability improvements. The company's growth has been steady but likely not explosive, characteristic of a specialty pharmaceutical player in niche markets.
Future Projections: Future projections would depend on the company's ability to identify and acquire new revenue-generating products, the performance of its existing portfolio, and potential market expansion. Analyst estimates, if available, would provide insights into projected revenue and earnings growth. Without specific analyst coverage or company guidance, projections are speculative.
Recent Initiatives: Recent initiatives would likely involve product line extensions, geographic market expansion, strategic partnerships, or the acquisition of new pharmaceutical assets. Specific details would require reviewing recent company press releases and investor relations materials.
Summary
Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company operating in niche hospital-based therapeutic and gastroenterology markets. Its strengths lie in its focused product strategy and established hospital relationships. However, it faces significant challenges due to its limited pipeline, smaller scale compared to competitors, and the inherent risks of the pharmaceutical industry. Future success hinges on strategic product acquisitions and effective commercialization of its existing portfolio.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC filings (10-K, 10-Q)
- Financial news and analysis websites
- Industry reports
Disclaimers:
This analysis is based on publicly available information and may not be exhaustive. Financial data and market share figures are estimates and subject to change. Investing in pharmaceutical companies carries inherent risks. This is not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cumberland Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Nashville, TN, United States | ||
IPO Launch date 2009-08-11 | Founder, Chairman, President & CEO Mr. A. J. Kazimi MBA | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 91 | Website https://www.cumberlandpharma.com |
Full time employees 91 | Website https://www.cumberlandpharma.com | ||
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, an injection for the prevention of nausea and vomiting for patients receiving chemotherapy treatment; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops ifetroban, a product candidate that has completed Phase II clinical trials for the treatment of the cardiomyopathy associate with Duchenne muscular dystrophy, hepatorenal syndrome, portal hypertension, and aspirin-exacerbated respiratory disease; and is in Phase II clinical trial for the treatment of systemic sclerosis and idiopathic pulmonary fibrosis. Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.